^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    KRAS G61H

    i
    Other names: KRAS, KRAS1, KRAS2, Kirsten rat sarcoma viral oncogene homolog
    Entrez ID:
    3845
    Related biomarkers:
    Expression
    Mutation
    CNA
    Others
    Associations

    News

    Trials
    almost2years
    HER2 copy number variation in non-small cell lung cancer (NSCLC) (ESMO 2022)
    As further line of treatment, 5 patients received trastuzumab: 4 in combination with chemotherapy and 1 as monotherapy, with 1 stabilization of disease as best response. 3 patients received nivolumab (1 partial response and 1 stable disease) and 3 a targeted therapy (anti ALK, EGFR, BRAF). Conclusions Increased HER2 GCN was found in 9% of patients with unresectable NSCLC, was not correlated to particular clinical characteristics, but frequently occurred with other molecular alterations. Its clinical actionability and the correlation with protein expression deserve further characterization.
    PD(L)-1 Biomarker
    |
    EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • MET (MET proto-oncogene, receptor tyrosine kinase) • FGFR1 (Fibroblast growth factor receptor 1)
    |
    BRAF V600E • KRAS mutation • EGFR mutation • KRAS G12C • BRAF V600 • HER-2 mutation • EGFR exon 19 deletion • MET amplification • KRAS G12D • ALK rearrangement • FGFR1 amplification • HER-2 exon 20 insertion • MET mutation • KRAS G12 • HER-2 exon 20 mutation • FGFR1 rearrangement • HER-2 exon 23 mutation • KRAS G61 • KRAS G61H
    |
    Opdivo (nivolumab) • Herceptin (trastuzumab)